Humacyte News and Activities
Presence
Humacyte develops and manufactures regenerative human tissues and vascular grafts using a biotechnology process that can be applied across a wide range of diseases and conditions. Its products mainly target the medical and healthcare sectors, offering solutions for vascular diseases, surgical bypasses, and trauma repair.
- Human acellular vessels (HAVs)
- Regenerative tissue products
- Bioengineered arteries
Employees: 100
Humacyte is one of the...
Humacyte is a company listed under the stock ticker HUMA (US).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Humacyte
- Laura Niklason, Director, President and Chief Executive Officer
- Michael Constantino, Director
- Todd Pope, Director
Create your alert
to follow the executive moves at Humacyte.
Biotechnology
Humacyte has 2,339 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).
Popular M&A news in Biotechnology
- Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
- Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
- The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).
Popular contacts in Biotechnology
News
Press releases by Humacyte
- Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 | Humacyte, Inc.
- Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update | Humacyte, Inc.
- Humacyte Statement on Recent Attacks | Humacyte, Inc.
- Press Releases | Humacyte, Inc.
- Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 | Humacyte, Inc.
- Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update | Humacyte, Inc.
- Humacyte Statement on New York Times Article | Humacyte, Inc.
- Humacyte, Inc. Announces Proposed Public Offering of Common Stock | Humacyte, Inc.
- Humacyte, Inc. Announces Pricing of Public Offering of Common Stock | Humacyte, Inc.
- Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics | Humacyte, Inc.
- View more press releases Close
Social media about Humacyte
- Humacyte on Wikipedia, Google News & Yahoo Finance
- Humacyte on LinkedIn, Twitter & YouTube
